OverviewSuggest Edit

QIAGEN N.V., through its subsidiaries, provides technologies and products for preanalytical sample preparation and linked molecular assay solutions. The company also supplies diagnostic kits, tests, and assays for human and veterinary molecular diagnostics. Technologies Sample Technologies: The company’s sample technologies provide access to the content of biological samples. These include solutions for the collection, stabilization, purification, handling and storage of any analyte (deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and protein) from any sample (blood, bone, and tissue).
TypePublic
Founded1984
HQHilden, DE
Websiteqiagen.com
Employee Ratings3.7
Overall CultureA

Latest Updates

Employees (est.) (Feb 2021)5,300
Share Price (Feb 2021)€41.4 (-2%)
Cybersecurity ratingBMore

Key People/Management at Qiagen

Thierry Bernard

Thierry Bernard

Chief Executive Officer
Stéphane Bancel

Stéphane Bancel

Supervisory Director
Lawrence A. Rosen

Lawrence A. Rosen

Chairman of the Supervisory Board and Supervisory Director
Dominic O'Neil

Dominic O'Neil

Associate Director DNA Product Development
Stephany Foster

Stephany Foster

Senior Vice President, Head of Human Resources
Metin Colpan

Metin Colpan

Supervisory Director
Show more

Qiagen Office Locations

Qiagen has offices in Hilden, Bodman-Ludwigshafen, Germantown, Holmesglen and in 19 other locations
Hilden, DE (HQ)
1 Qiagen Str.
Bodman-Ludwigshafen, DE
Bodenseeallee 20
Antwerpen, BE
Quellinstraat 49
Toronto, CA
4400-181 Bay St
Shenzhen Shi, CN
4 Kewen Rd, Nanshan Qu
København, DK
Fruebjergvej 3
Show all (27)

Qiagen Financials and Metrics

Qiagen Revenue

Market capitalization (25-Feb-2021)

9.4b

Closing stock price (25-Feb-2021)

41.4
Qiagen's current market capitalization is €9.4 b.
Show all financial metrics

Qiagen Cybersecurity Score

Cybersecurity ratingPremium dataset

B

82/100

SecurityScorecard logo

Qiagen Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Qiagen Online and Social Media Presence

Embed Graph

Qiagen Company Culture

  • Overall Culture

    A

    82/100

  • CEO Rating

    A+

    90/100

  • Compensation

    B+

    78/100

Learn more on Comparably

Qiagen News and Updates

Global Oncology Molecular Diagnostics Market Report 2020-2030: Major Players are Abbott Diagnostics, BD, Cepheid, Danaher, Beckman Coulter, Leica Biosystems, Gen Probe, Qiagen, Roche, Siemens

DUBLIN, Feb. 17, 2021 /PRNewswire/ -- The "Oncology Molecular Diagnostics Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. Major players in the oncology molecular diagnostics market are Abbott Diagnostics, Becton...

Tecan and Qiagen Collaborate to Automate Pre-Analytical Processing of Whole Blood Samples

Tecan has launched the Fluent® Mix and Pierce Workstation* to provide end-to-end automation for whole blood pipetting in clinical environments. read more

: Qiagen stock rises on announced COVID-19 test

Qiagen NV QGEN shares rose in the extended session Wednesday after the Netherlands-based medical diagnostics company said it will begin selling a portable COVID-19 test in the United States. Qiagen shares rose 4% after hours, following a 0.9% rise in the regular session to close at $46.51. Called t…

Qiagen to launch rapid coronavirus test it says could be used in airports and stadiums

Qiagen CEO Thierry Bernard said the antigen tests are meant to supplement, not replace, the molecular, or PCR, tests, the most accurate tests on the market.

Press release from Davidson Kempner regarding Qiagen

LONDON, Aug. 13, 2020 /PRNewswire/ -- Davidson Kempner is pleased that the majority of investors have rejected the wholly inadequate offer made by Thermo Fisher Scientific. The low acceptance level of 47.02% is a clear signal that there is widespread confidence in the long-term prospects...

Press release from Davidson Kempner regarding Qiagen

LONDON, Aug. 13, 2020 /PRNewswire/ -- Davidson Kempner is pleased that the majority of investors have rejected the wholly inadequate offer made by Thermo Fisher Scientific. The low acceptance level of 47.02% is a clear signal that there is widespread confidence in the long-term prospects...
Show more

Qiagen Blogs

Using the Interactive Filter Cascade in QCI Interpret Translational

Whole-exome sequencing (WES) using next-generation sequencing (NGS) technology is a powerful tool for investigating variants linked to genetic disease. It... The post Using the Interactive Filter Cascade in QCI Interpret Translational appeared first on Bioinformatics Software and Services | QIAGEN D…

Overcoming Challenges in Variant Filtering and Prioritization

Next-generation sequencing (NGS) techniques allow high-throughput detection of a vast amount of genetic variations in a cost-effective manner. However, there... The post Overcoming Challenges in Variant Filtering and Prioritization appeared first on Bioinformatics Software and Services | QIAGEN Digi…

The key to target and biomarker discovery

Hint: The secret is in the biological context Today’s discovery scientists are challenged with identifying new biomarkers and therapeutic targets... The post The key to target and biomarker discovery appeared first on Bioinformatics Software and Services | QIAGEN Digital Insights.

QIAGEN Digital Insights Publication Roundup (Spring 2021)

Read about how researchers across the world are using QIAGEN Digital Insights solutions to accelerate their work in a variety... The post QIAGEN Digital Insights Publication Roundup (Spring 2021) appeared first on Bioinformatics Software and Services | QIAGEN Digital Insights.

HGMD Professional 2020.4 Release

The Winter 2020 Release of the Human Gene Mutation Database (HGMD) Professional is available, expanding the world’s largest collection of... The post HGMD Professional 2020.4 Release appeared first on Bioinformatics Software and Services | QIAGEN Digital Insights.

Learn what’s new in the QIAGEN CLC Genomics version 21 (v21) release

Check out the new features of QIAGEN CLC Genomics Are you struggling to find a bioinformatics analysis tool that meets... The post Learn what’s new in the QIAGEN CLC Genomics version 21 (v21) release appeared first on Bioinformatics Software and Services | QIAGEN Digital Insights.
Show more

Qiagen Frequently Asked Questions

  • When was Qiagen founded?

    Qiagen was founded in 1984.

  • Who are Qiagen key executives?

    Qiagen's key executives are Thierry Bernard, Stéphane Bancel and Lawrence A. Rosen.

  • How many employees does Qiagen have?

    Qiagen has 5,300 employees.

  • Who are Qiagen competitors?

    Competitors of Qiagen include Integrated DNA Technologies, VWR and Stemina Biomarker Discovery.

  • Where is Qiagen headquarters?

    Qiagen headquarters is located at 1 Qiagen Str., Hilden.

  • Where are Qiagen offices?

    Qiagen has offices in Hilden, Bodman-Ludwigshafen, Germantown, Holmesglen and in 19 other locations.

  • How many offices does Qiagen have?

    Qiagen has 27 offices.